## 5 Conclusions  
In conclusion, protein and/or mRNA expression levels of SATB1, SMAD3, Ezrin and \(\beta\)-catenin are significantly altered in PAC and may correlate with some tumor features as well as provide prognostic information as single indicators, and even better when combined.  
**Supplementary Materials:** The following are available online at [[https://www.mdpi.com/article/10.3390/app12010306/s1](https://www.mdpi.com/article/10.3390/app12010306/s1)]([https://www.mdpi.com/article/10.3390/app12010306/s1](https://www.mdpi.com/article/10.3390/app12010306/s1)), Figure S1. Kaplan-Meier curve for overall survival in patients with pancreatic ductal adenocarcinomas by nuclear/cytoplasmic SATB1 protein expression. \(p\) value was calculated using the log-rank test. Figure S2. Kaplan-Meier curve for overall survival in patients with pancreatic ductal adenocarcinomas by cytoplasmic \(\beta\)-catenin protein expression. \(p\) value was calculated using the log-rank test. Table S1. Univariate analysis of prognostic factors by [PERSON] proportional hazard model in own cohort for cytoplasmic \(\beta\)-catenin protein expression. Table S2. Multivariate analysis of prognostic factors by [PERSON] proportional hazard model in own cohort for cytoplasmic \(\beta\)-catenin protein expression. Table S3. Parameters of network determined using the network analyzer Cytoscape plugin. Table S4. Immunohistochemistry-subrochemical expression of cytoplasmic \(\beta\)-catenin proteins and their relationship with clinicopathological features of PDAC patients. Table S5. Univariate analysis of prognostic factors by [PERSON] proportional hazard model in own cohort for cytoplasmic \(\beta\)-catenin protein expression. Table S6. Multivariate analysis of prognostic factors by [PERSON] proportional hazard model in own cohort for cytoplasmic \(\beta\)-catenin protein expression.  
**Author Contributions:** Conceptualization: D.G., J.D. and A.K.-W.; data curation: J.D., A.K.-W., P.A. and A.G.; formal analysis: J.D., A.K.-W., P.C. and K.M.; funding acquisition: A.K.-W.; investigation: J.D.; methodology: J.D. and P.A.; project administration: A.K.-W.; staining evaluation: [PERSON] and N.S.-M.; supervision: A.K.-W. and [PERSON]; writing--original draft: [PERSON], A.K.-W. and [PERSON]; writing--review and editing: [PERSON] and A.K.-W. All authors have read and agreed to the published version of the manuscript.  
**Funding:** This research was funded by Nicolaus Copernicus University in Torun, Faculty of Medicine, Collegium Medicium in Bydgoszcz, research task no. MN-1/WL/2019.  
**Institutional Review Board Statement:** This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of Nicolaus Copernicus University in Torun, Collegium Medicium in Bydgoszcz (KB 342/2020; 23 June 2020).  
**Informed Consent Statement:** Patient consent was waived due to the retrospective nature of the study. The requirement for informed consent was waived by the Institutional Ethics Committee of Nicolaus Copernicus University in Torun, Collegium Medicium in Bydgoszcz.  
**Data Availability Statement:** Publicly available datasets were analyzed in this study. These data can be found here: [[http://www.cbioportal.org/study/summary?id=paad_tcga_pan_can_atlas_2018](http://www.cbioportal.org/study/summary?id=paad_tcga_pan_can_atlas_2018)]([http://www.cbioportal.org/study/summary?id=paad_tcga_pan_can_atlas_2018](http://www.cbioportal.org/study/summary?id=paad_tcga_pan_can_atlas_2018)) (accessed on 3 July 2020); [[https://xenabrowser.net](https://xenabrowser.net)]([https://xenabrowser.net](https://xenabrowser.net)) (accessed on 3 July 2021). Our own data presented in this study are available on request from the corresponding author. The data are not publicly available due to ethical restrictions.